Published in J Obstet Gynaecol Can on December 01, 2002
Serous Cystadenoma and Fibrothecoma: A Rare Combination in Collision Tumor of Ovary with Pseudo-Meigs Syndrome. J Pathol Transl Med (2015) 0.75
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Structuring an inter-sector research partnership: a negotiated zone. Soz Praventivmed (2006) 3.99
Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol (2005) 2.62
Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer: case report. Gynecol Oncol (2006) 2.23
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can (2007) 2.09
Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature. Gynecol Oncol (2004) 1.85
Preoperative bowel preparation in gynecologic oncology: a review of practice patterns and an impetus to change. Int J Gynecol Cancer (2011) 1.39
The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol (2011) 1.38
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol (2013) 1.36
Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res (2006) 1.23
Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab (2004) 1.19
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet (2006) 1.17
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol (2005) 1.13
Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol (2006) 1.11
Long-term outcome of a randomized study comparing three techniques of conization: cold knife, laser, and LEEP. Eur J Obstet Gynecol Reprod Biol (2003) 1.09
Diagnosis and management of cervical cancer. BMJ (2007) 1.09
The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle (2013) 1.08
Laparoscopic sentinel node mapping in early-stage cervical cancer. Gynecol Oncol (2003) 1.05
No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result. Cancer Epidemiol Biomarkers Prev (2005) 1.04
First-line therapy in ovarian cancer trials. Int J Gynecol Cancer (2011) 1.03
Reliability of a computerized version of the Pediatric Canadian Triage and Acuity Scale. Acad Emerg Med (2007) 1.01
Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol (2008) 1.00
Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol (2006) 0.99
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat (2012) 0.98
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget (2014) 0.98
Angiogenic properties of myofibroblasts isolated from normal human skin wounds. Angiogenesis (2012) 0.97
Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors. J Cell Physiol (2004) 0.94
Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet (2005) 0.94
Epidermis promotes dermal fibrosis: role in the pathogenesis of hypertrophic scars. J Pathol (2005) 0.94
Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab (2010) 0.93
The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res (2004) 0.92
Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin Rheumatol (2004) 0.91
Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab (2010) 0.91
Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer (2006) 0.90
Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol (2008) 0.90
Value of sentinel node mapping in cancer of the cervix. Gynecol Oncol (2011) 0.90
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol (2011) 0.89
Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Gynecol Oncol (2012) 0.89
Mixed ovarian large cell neuroendocrine carcinoma, mucinous adenocarcinoma, and teratoma: a report of two cases and review of the literature. Pathol Res Pract (2009) 0.87
Should ovaries be removed or not in (early-stage) adenocarcinoma of the uterine cervix: a review. Gynecol Oncol (2014) 0.86
No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. Genet Test (2006) 0.86
Primary villoglandular adenocarcinoma of cloacogenic origin of the vulva. Hum Pathol (2004) 0.86
44-55-66-PM, a mnemonic that improves retention of the Ottawa Ankle and Foot Rules: a randomized controlled trial. Acad Emerg Med (2010) 0.86
Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population. J Genet Couns (2008) 0.85
Mucinous ovarian tumors of Mullerian-type: an analysis of 17 cases including borderline tumors and intraepithelial, microinvasive, and invasive carcinomas. Int J Gynecol Pathol (2005) 0.85
Metastatic gastrointestinal tract cancer presenting as ovarian carcinoma. J Obstet Gynaecol Can (2003) 0.84
Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One (2011) 0.84
Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population. Int J Gynecol Cancer (2012) 0.84
Simple vaginal trachelectomy in early-stage low-risk cervical cancer: a pilot study of 16 cases and review of the literature. Int J Gynecol Cancer (2013) 0.84
SOGC–GOC–SCC Joint Policy Statement. No. 255, March 2011. Cervical cancer prevention in low-resource settings. J Obstet Gynaecol Can (2011) 0.84
Radical vaginal trachelectomy: a fertility-preserving option for young women with early stage cervical cancer. Gynecol Oncol (2005) 0.82
Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. Eur J Hum Genet (2011) 0.82
Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol (2009) 0.82
Fertility-preserving options for cervical cancer. Oncology (Williston Park) (2006) 0.82
The role of adjuvant therapy in endometrial cancer. J Obstet Gynaecol Can (2013) 0.81
Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells. PLoS One (2013) 0.81
Primitive clear cell carcinoma of the vagina treated conservatively. J Obstet Gynaecol Can (2009) 0.81
The significance of surgical staging in intermediate-risk endometrial cancer. Gynecol Oncol (2011) 0.81
Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol (2012) 0.81
Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families. Fam Cancer (2007) 0.80
Epidemiology and investigations for suspected endometrial cancer. J Obstet Gynaecol Can (2013) 0.80
A phase II trial of JM-216 in cervical cancer: an NCIC CTG study. Gynecol Oncol (2002) 0.80
Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev (2007) 0.80
A new alternative splice variant of BRCA1 containing an additional in-frame exon. Biochim Biophys Acta (2005) 0.79
Prospective study on the treatment of lower-extremity chronic venous and mixed ulcers using tissue-engineered skin substitute made by the self-assembly approach. Adv Skin Wound Care (2013) 0.79
A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol (2013) 0.79
Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges. Fam Cancer (2006) 0.79
Oral dimenhydrinate versus placebo in children with gastroenteritis: a randomized controlled trial. Pediatrics (2012) 0.79
Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families. Int J Cancer (2008) 0.79
Laparoscopically assisted vaginal radical hysterectomy. Best Pract Res Clin Obstet Gynaecol (2005) 0.79
Innovations in the treatment of invasive cervical cancer. Cancer (2003) 0.78
Negative sentinel lymph node accurately predicts negative status of pelvic lymph nodes in uterine cervix carcinoma. Gynecol Oncol (2006) 0.78
A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation. Gynecol Oncol (2012) 0.78
Indication and method of frozen section in vaginal radical trachelectomy. Int J Gynecol Pathol (2009) 0.78
Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy. J Obstet Gynaecol Can (2004) 0.78
Vaginal radical trachelectomy in the treatment of cervical cancer: the role of frozen section. Int J Gynecol Pathol (2004) 0.78
Early cervical carcinoma and fertility-sparing treatment options: MR imaging as a tool in patient selection and a follow-up modality. Radiographics (2014) 0.78
Using imiquimod for genital warts in female patients. J Womens Health (Larchmt) (2004) 0.77
The role of surgery in endometrial cancer. J Obstet Gynaecol Can (2013) 0.77
Is a More Comprehensive Surgery Necessary in Patients With Uterine Serous Carcinoma? Int J Gynecol Cancer (2015) 0.76
Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. Int J Gynecol Cancer (2016) 0.76
Pilot study of radical hysterectomy versus radical trachelectomy on sexual distress. J Sex Marital Ther (2013) 0.76
Sentinel node evaluation in gynecologic cancer. Oncology (Williston Park) (2004) 0.76
Sensitivity of myofibroblasts to H2O2-mediated apoptosis and their antioxidant cell network. J Cell Physiol (2004) 0.75
Long-distance air transport of an infant weighing less than 500 g: Is it in the patient's best interest? Paediatr Child Health (2011) 0.75
HRT use among women tested for BRCA1/2 mutations following publication of the women's health initiative study results. J Obstet Gynaecol Can (2005) 0.75
Surgical venous thromboprophylaxis: a cross-sectional survey of canadian gynaecologic oncologists. J Obstet Gynaecol Can (2012) 0.75
Pelvic-Floor Properties in Women Reporting Urinary Incontinence After Surgery and Radiotherapy for Endometrial Cancer. Phys Ther (2017) 0.75
Profiling of Endogenous Estrogens, Their Precursors, and Metabolites in Endometrial Cancer Patients: Association with Risk and Relationship to Clinical Characteristics. Endocrinology (2011) 0.75
Data Set for the Reporting of Carcinomas of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Int J Gynecol Pathol (2017) 0.75
Place of Schauta's radical vaginal hysterectomy. Best Pract Res Clin Obstet Gynaecol (2011) 0.75